WEBULL
News
MEDXF
1.910
+1.06%
0.020
Weekly Report: what happened at MEDXF last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at MEDXF last week (1117-1121)?
Weekly Report · 11/24 10:04
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
Newsfile · 11/20 12:30
Medexus Pharmaceuticals Secures US$51 Million Credit Facilities with National Bank of Canada
Reuters · 11/17 13:34
Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
Newsfile · 11/17 13:30
Weekly Report: what happened at MEDXF last week (1110-1114)?
Weekly Report · 11/17 10:04
Medexus Pharmaceuticals reports FQ2 results
Seeking Alpha · 11/13 16:16
Medexus Pharma Q2 revenue misses estimates
Reuters · 11/12 23:17
Medexus Pharmaceuticals Releases MD&A for Q2 2026
Reuters · 11/12 23:08
Medexus Reports Strong Q2 2026 Results Driven by GRAFAPEX Performance
Reuters · 11/12 23:07
BRIEF-Medexus Pharmaceuticals Q2 Revenue USD 24.741 Million Vs. IBES Estimate USD 25.6 Million
Reuters · 11/12 23:07
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Newsfile · 11/12 23:06
Weekly Report: what happened at MEDXF last week (1103-1107)?
Weekly Report · 11/10 10:02
Medexus Schedules Second Fiscal Quarter 2026 Conference Call
Newsfile · 11/04 22:30
Weekly Report: what happened at MEDXF last week (1027-1031)?
Weekly Report · 11/03 10:03
Weekly Report: what happened at MEDXF last week (1020-1024)?
Weekly Report · 10/27 10:05
Weekly Report: what happened at MEDXF last week (1013-1017)?
Weekly Report · 10/20 10:02
Weekly Report: what happened at MEDXF last week (1006-1010)?
Weekly Report · 10/13 10:05
Weekly Report: what happened at MEDXF last week (0929-1003)?
Weekly Report · 10/06 10:02
Weekly Report: what happened at MEDXF last week (0922-0926)?
Weekly Report · 09/29 10:02
More
Webull provides a variety of real-time MEDXF stock news. You can receive the latest news about Medexus Pharmace through multiple platforms. This information may help you make smarter investment decisions.
About MEDXF
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of hematology-oncology and allergy, dermatology, and rheumatology. It operates through two product portfolios: Medexus Pharma Canada and Medexus Pharma. Its lead products are IXINITY (US), GRAFAPEX (US), Trecondyv (Canada), Rupall (Canada), Rasuvo (US), Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.